SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's GOOG is trending due to growing investor confidence in its AI capabilities, particularly with the recent unveiling of Gemini 3, which is seen as a strong competitor to existing AI models. Community discussion revolves around GOOG potentially overtaking NVDA in market capitalization, with some analysts suggesting Google's long-term growth potential is being re-evaluated, leading to a shift in market sentiment.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet (GOOGL) is trending as investors discuss its potential to lead in AI, fueled by positive reviews of its Gemini 3 model and a recent investment by Berkshire Hathaway. Community members are weighing in on whether the stock's rapid growth is sustainable, while highlighting its competitive position against companies like Nvidia and OpenAI. Some traders are noting technical indicators that may signal a pullback is coming.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is trending upwards as the community discusses potential M&A activity and positive momentum within the biotech sector. Positive clinical data and new FDA pathways are also sparking interest, while some analysts point to attractive valuations compared to peers. Concerns about data integrity for specific companies are also circulating.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPM is trending amid discussions around potential investigations related to Jeffrey Epstein, its relationship with crypto companies like $MSTR, and overall sentiment regarding the financial sector. Some traders are considering shorting the stock, while others point to positive technical indicators and potential upside. The community is also discussing JPM's role in the broader market and its impact on individual stocks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending amid discussions about its role in AI, particularly following reports that Google's Gemini 3 model utilizes Broadcom's TPUs, sparking debates about competition with Nvidia. Bullish sentiment and high price targets are fueled by expectations of strong earnings, while some traders are closely monitoring technical indicators and potential pullbacks. The community is also weighing the stock's valuation and its long-term potential within the growing AI landscape.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as community members rally around its meme-driven narrative and organic growth on the SOL network. The community, known for its active presence and lighthearted approach, emphasizes that the "infection" is spreading, with community members using the hashtag #PMV. Participants suggest that the coin's current levels present an attractive entry point.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending amid discussions about immigration policies and detention facilities, with community members sharing news articles and discussing potential impacts on the company. Some traders are highlighting options strategies, while others are debating the company's financial outlook and potential for government contracts in light of political developments. The stock's valuation and buyback program are also key talking points.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

Karrat is trending amid community excitement and speculation about potential near-term gains, with some eyeing a 10x run. Discussions revolve around accumulation strategies, possible breakouts, and the coin's potential to trade independently of larger cryptocurrencies like Bitcoin and Ethereum, while some warn of dilution and potential scams.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad ($MON) is drawing mixed reactions, with some users alleging VC rug pulls and others speculating on potential Coinbase involvement or range formation. The community is actively discussing bottom price discovery and comparing it to established blockchains like Solana and Ethereum, while also pointing out concerns about low engagement.

Mason Capital Fund Trust - Fundamentals First ETF

KNOW Labs is trending, with discussions focusing on the company's plan to apply for listing on the NYSE American under the symbol "KNW." The community is also comparing KNOW's technology to competitors in the medical device space, specifically highlighting its non-invasive glucose monitoring device. Some users are speculating about a potential gamma squeeze and NASDAQ listing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Pasithea Therapeutics garnered heightened retail buzz on Tuesday after the firm announced preclinical results showing that its experimental drug, PAS-004, effectively blocked ETS2 signaling, which controls inflammation in IBD and other immune conditions.Research from the Francis Crick Institute found PAS-004 more effective than selumetinib at reducing the expression of ETS2-regulated genes and macrophage functions essential for cytokine production and phagocytosis.Pasithea Therapeutics shares ended Tuesday at $0.98, with a 3.77% gain, but they fell back 4.17% to $0.94 during after-hours trading.According to Lee, who published a 2024 Nature paper identifying ETS2 as an essential regulator of IBD-related inflammation, the findings suggest PAS-004 could provide broader inhibition of inflammatory pathways compared to selumetinib and therapies that target individual cytokines or rely on JAK inhibition.According to Pasithea CEO Tiago Reis Marques, data findings show PAS-004's potential for treating chronic inflammatory diseases and its existing cancer application.&nbsp;Safety data from Phase 1 trials in advanced cancer patients suggest that the drug appears to show good tolerance in wider therapeutic uses.The firm announced its plan to move PAS-004 into proof-of-concept research targeting inflammatory disorders, including IBD and ankylosing spondylitis.On Stocktwits, retail sentiment was ‘bullish’ amid a 7,450% surge in 24-hour message volume.One user&nbsp;was “infuriated” after exiting a position in Pasithea Therapeutics (KTTA) at a loss after buying in at $1.18 and selling at $0.92, only to see the stock rise afterward.<stembedurl>https://stocktwits.com/Cdeezhands/message/615259857</stembedurl>Another user noted that Pasithea’s recent news was encouraging and pointed to the stock’s price movement from around $2.08 in April to $2.48 in early May as a sign of potential for organic upside.<stembedurl>https://stocktwits.com/stocktrade77/message/615239372</stembedurl>The stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Pasithea Therapeutics Stock Draws Retail Buzz As Early Data Shows Potential In Treating Inflammatory Diseases

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. 

Equity

The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases. The company plans to advance PAS-004 into further studies targeting inflammatory conditions.

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

Shares of Pasithea Therapeutics Corp. (KTTA) soared as high as about 150% on Tuesday morning before paring back most of the gains after it announced positive data from its ongoing Phase 1 trial of PAS-004 in advanced cancer patients.PAS-004 is a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other mitogen-activated protein kinase (MAPK) pathway driven cancer indications.The clinical-stage biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/06/3074902/0/en/Pasithea-Therapeutics-Reports-Positive-Pharmacodynamic-Results-Demonstrating-Robust-Target-Engagement-from-its-Ongoing-Phase-1-Clinical-Trial-of-PAS-004.html">said</a> that several patients achieved stable disease and tumor shrinkage while on the treatment.A patient being treated with 15-milligram capsules of PAS-004 with stage 4 pancreatic cancer achieved a tumor volume reduction of 9.8% over 5 months of PAS-004 treatment, the company said. The patients currently remain in the study, it added.Certain biomarkers also confirmed the capsule’s MEK inhibitor activity and substantial target engagement, the company said.The Phase 1 trial is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumors.The recently announced data include results from patients treated with 8mg, 15mg, and 4mg tablets of PAS-004.In April, the company also dosed three subjects with 30mg capsules of PAS-004.The company then said it expects to complete enrollment of all patients in the trial by the end of 2025.On Stocktwits, retail sentiment around Pasithea jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_06_at_10_44_26_AM_png_4ec77b8998.webp" alt="KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits" width="633" height="62"><figcaption>KTTA's Sentiment Meter and Message Volume as of 10:45 a.m. ET on May 6, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/KTTA">KTTA stock</a> is down by about 42% this year and by about 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/economist-kenneth-rogoff-believes-trump-trade-policy-is-speeding-up-dollar-decline/chiIJtJRbS7">Economist Kenneth Rogoff Believes Trump’s Trade Policy Is Speeding Up Dollar’s Decline, Calls Navarro President’s ‘Rasputin’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated

The clinical-stage biotechnology company said several patients achieved stable disease and tumor shrinkage while on the treatment.

Shares of Pasithea Therapeutics Corp. (KTTA) surged nearly 47% on Thursday, closing at a two-month high, after an external committee approved advancing its cancer drug trial to the next dosing cohort.The news also resulted in the company's stock drawing the highest jump in retail investor chatter among healthcare stocks on Stocktwits.&nbsp;Message volume about KTTA soared by a whopping 48,000% by late Thursday, while sentiment flipped to 'extremely bullish' from 'bearish' a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/KTTA_sentiment_and_message_volume_April_10_png_57f0ce9213.webp" alt="KTTA sentiment and message volume April 10.png" width="1318" height="316"><figcaption>KTTA sentiment and message volume April 10. | source: Stocktwits</figcaption></figure>Pasithea said that its Phase 1 clinical trial of PAS-004 for advanced cancer has been cleared to advance to Cohort 6 (30mg capsule), following a recommendation from the independent Safety Review Committee.&nbsp;The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities (DLTs) reported.Notably, none of the first 19 patients — across both capsule and tablet formulations — have experienced rash, a common and often dose-limiting side effect seen with competitor MEK inhibitors.The ongoing trial is a multi-center, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004.&nbsp;One bullish watcher said the stock "will probably open at $2.18" on Friday, implying a more than 35% jump from the last close.<stembedurl>https://stocktwits.com/Nifty_Trader/message/611306648</stembedurl>Another user recommended holding the stock for a week or two and it "should be at $5 or $7."<stembedurl>https://stocktwits.com/MommoTrader/message/611306390</stembedurl><a href="https://stocktwits.com/symbol/KTTA">Pasithea stock</a> has lost nearly 50% this year. Shares were up marginally in Thursday's after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort

The decision was based on safety data from three patients in Cohort 5, with no dose-limiting toxicities reported.

11 Undervalued Stocks for Less Than $50 in April 2024

These inexpensive and undervalued stocks are top performers with strong upside potential based on their price-to-book ratio

 Steve Russell / Contributor

Neuroscience-focused biotechnology firm...

Pasithea Therapeutics Corp trading halted, volatility trading pause

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern...

Pasithea Therapeutics announces invention of crystalline form of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO...

Pasithea Therapeutics announces FDA acceptance of IND application for PAS-004

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

Pasithea Therapeutics Corp

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

KTTA
Pasithea Therapeutics Corp

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KTTA News

KTTAPasithea Therapeutics Corp